Aminoglycoside drugs in clinical practice: An evidence-based approach

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 2, 2009, Pages 246-251

  Leibovici, Leonard ^a,b   Vidal, Liat ^a,b   Paul, Mical ^a,b,c  

^a Department of Medicine E ^*  (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

lactams; Aminoglycosides; Evidence based medicine; Synergism

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN; COLISTIN; GENTAMICIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL ENDOCARDITIS; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYSTIC FIBROSIS; DIARRHEA; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECONOMIC EVALUATION; EVIDENCE BASED PRACTICE; GRAM NEGATIVE INFECTION; GRAM POSITIVE COCCI; HUMAN; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PYELONEPHRITIS; REVIEW; SEPSIS; SINGLE DRUG DOSE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 58849120521     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn469     Document Type: Review

References (36)

1. Freundlich M, Thomsen RW, Pedersen L et al. Aminoglycoside treatment and mortality after bacteraemia in patients given appropriate empirical therapy. A Danish hospital-based cohort study. J Antimicrob Chemother 2007; 60: 1115-23.
2. Stabell N, Nordal E, Stensvold E et al. Febrile neutropenia in children with cancer: A retrospective Norwegian multicentre study of clinical and microbiological outcome. Scand J Infect Dis 2008; 40: 301-7.
3. Torfoss D, Høiby EA, Tangen JM et al. Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: A prospective, randomized, multicentre trial. J Antimicrob Chemother 2007; 59: 711-7.
4. Rajendran SD, Madhusudan Rao Y, Karthikeyan VP. Evaluation of target concentration intervention strategy of gentamicin therapy in a malnourished patient population of south India. Indian J Med Res 2005; 122: 511-7.
5. Paul M, Soares-Weiser K, Leibovici L. β-Lactam monotherapy versus β-lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003; 326: 1111-5.
6. Paul M, Ben-uri Silbiger IS, Soares-Weiser K et al. β-Lactam monotherapy versus β-lactam-aminoglycoside combination therapy for treating sepsis. BMJ 2004; 328: 668-72.
7. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev 2005; issue 2: CD002007. DOI:10.1002/14651858.CD002007.pub2.
8. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4: 519-27.
9. Paul M, Leibovici L. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect Dis 2005; 5: 192-4.
10. Bliziotis IA, Samonis G, Vardakas KZ et al. Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance: A meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41: 149-58.
11. Leibovici L, Paul M, Poznanski O et al. Monotherapy versus β-lactam-aminoglycoside combination treatment for gram-negative bacteremia: A prospective, observational study. Antimicrob Agents Chemother 1997; 41: 1127-33.
12. Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycosides in combination with a β-lactam for the treatment of bacterial endocarditis: A meta-analysis of comparative trials. J Antimicrob Chemother 2006; 57: 639-47.
13. Vidal L, Gafter-Gvili A, Borok S et al. Efficacy and safety of aminoglycoside monotherapy: Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007; 60 247-57.
14. Bailey JA, Virgo KS, Dipiro JT et al. Aminoglycosides for intra-abdominal infection: Equal to the challenge? Surg Infect 2002; 3: 315-35.
15. Falagas ME, Matthaiou DK, Karveli EA et al. Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs. β-lactam monotherapy for the treatment of intra-abdominal infections. Aliment Pharmacol Ther 2007; 25: 537-56.
16. Wong PF, Gilliam AD, Kumar S et al. Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst Rev 2005; issue 2: CD004539. DOI:10.1002/ 14651858.CD004539.pub2.
17. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Ann Intern Med 1996; 124: 717-25.
18. Barza M, Ioannidis JP, Cappelleri JC et al. Single or multiple daily doses of aminoglycosides: A meta-analysis. BMJ 1996; 312 338-44.
19. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV et al. Extended-interval aminoglycoside administration for children: A meta-analysis. Pediatrics 2004; 114: E111-8.
20. Aiken SK, Wetzstein GA. Once-daily aminoglycosides in patients with neutropenic fever. Cancer Control 2002; 9: 426-31.
21. Smyth AR, Tan KH. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2006; issue 3: CD002009. DOI:10.1002/14651858.CD002009.pub2.
22. Raveh D, Kopyt M, Hite Y et al. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. QJM 2002; 95: 291-7.
23. Buijk SE, Mouton JW, Gyssens IC et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002; 28: 936-42.
24. Bertino JS Jr, Booker LA, Franck PA et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167: 173-9.
25. Drusano GL, Ambrose PG, Bhavnani SM et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45: 753-60.
26. Gerding DN, Larson TA, Hughes RA et al. Aminoglycoside resistance and aminoglycoside usage: Ten years of experience in one hospital. Antimicrob Agents Chemother 1991; 35: 1284-90.
27. Hsueh PR, Chen WH, Luh KT. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents 2005; 26: 463-72.
28. Ma MY, Goldstein EJ, Friedman MH et al. Resistance of gram-negative bacilli as related to hospital use of antimicrobial agents. Antimicrob Agents Chemother 1983; 24: 347-52.
29. Leibovici L, Berger R, Gruenewald T et al. Departmental consumption of antibiotic drugs and subsequent resistance: A quantitative link. J Antimicrob Chemother 2001; 48: 535-40.
30. DANMAP. Use of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Bacteria from Food Animals, Foods and Humans in Denmark 2006; ISSN 1600-2032. www.danmap.org.
31. Bliziotis IA, Michalopoulos A, Kasiakou SK et al. Ciprofloxacin vs an aminoglycoside in combination with a β-lactam for the treatment of febrile neutropenia: A meta-analysis of randomized controlled trials. Mayo Clin Proc 2005; 80: 1146-56.
32. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: E394-434.
33. Elliott TS, Foweraker J, Gould FK et al. Guidelines for the antibiotic treatment of endocarditis in adults: Report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2004; 54: 971-81.
34. Stone SP, Cooper BS, Kibbler CC et al. The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection. J Antimicrob Chemother 2007; 59: 833-40.
35. Jana S, Deb JK. Molecular understanding of aminoglycoside action and resistance. Appl Microbiol Biotechnol 2006; 70: 140-50.
36. Nagai J, Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 2004; 19: 159-70.